Aescap Life Sciences Newsletter Q1 2022

The fund’s NAV fell 6.8% in the first half of March and then rose 10.8% in the second half. It seems that sentiment for biotech stocks has at least stabilized. The first quarter was a good period to include new companies in the portfolio.

Aescap Life Sciences Newsletter Q1 2022